Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Breast Neoplasms × Hydralazine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Uterine Cervical Neoplasms 1 Rectal Neoplasms 1 Breast Neoplasms 1

Interventions

Paclitaxel 24 Trastuzumab 19 Cyclophosphamide 16 Docetaxel 14 Doxorubicin 11 exemestane 10 Radiotherapy 10 Capecitabine 10 Letrozole 9 Carboplatin 9 Lapatinib 8 Fulvestrant 8 pembrolizumab 7 Goserelin 6 Anastrozole 6 palbociclib 5 eribulin 5 Therapeutics 5 Neoadjuvant Therapy 5 Chemotherapy, Adjuvant 5 Bevacizumab 5 Aromatase Inhibitors 5 tucatinib 4 abemaciclib 4 Vinorelbine 4 Taxes 4 Polymerase Chain Reaction 4 Mastectomy, Segmental 4 Magnetic Resonance Spectroscopy 4 Exercise 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00575978 2015-03-04

Hydralazine as Demethylating Agent in Breast Cancer

University of Arkansas

Phase 1/2 Withdrawn

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡